Dual GIP/GLP-1 Agonists: Tirzepatide for Diabetes and Weight Loss
Learn about tirzepatide (Mounjaro), the first dual GIP/GLP-1 agonist. Discover how it works, effectiveness, and what makes it different from other medications.
On this page
In 2022, a new diabetes medication arrived with results that stunned the medical community: tirzepatide (Mounjaro).
In clinical trials, it lowered A1C by up to 2.6% and caused weight loss of up to 22%—more than any diabetes medication before it.
What makes tirzepatide different? It's a dual agonist, activating not one but two hormone systems. The 2025 ADA guidelines recognize it as a first-line option for patients with type 2 diabetes and high weight concerns.
What Is Tirzepatide?
The First-in-Class Medication
Tirzepatide is the first medication in a new class: dual GIP/GLP-1 receptor agonists.
| Component | Action | Effect |
|---|---|---|
| GLP-1 agonism | Stimulates GLP-1 receptors | Increases insulin, reduces glucagon, slows emptying, increases fullness |
| GIP agonism | Stimulates GIP receptors | Increases insulin, may improve fat metabolism, additive to GLP-1 |
Why Target Two Hormones?
GLP-1 alone (Ozempic, Trulicity) is effective, but tirzepatide's dual action appears to be more effective than GLP-1 alone:
| Outcome | GLP-1 Alone | Tirzepatide (Dual) |
|---|---|---|
| A1C reduction | 1.0-1.8% | 1.8-2.6% |
| Weight loss | 5-15% | 15-22% |
How Tirzepatide Works
The Mechanisms
| Mechanism | Effect on Body |
|---|---|
| Increases insulin secretion | Glucose-dependent (more insulin when blood sugar high) |
| Decreases glucagon secretion | Reduces liver glucose production |
| Slows gastric emptying | Increases fullness after meals |
| Acts on hypothalamus | Reduces appetite, increases satiety |
| Improves insulin sensitivity | May enhance fat metabolism |
| Increases energy expenditure | Possible GIP effect |
Why GIP Matters
GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone with complex effects:
| Traditional View | Emerging Understanding |
|---|---|
| "Inert" in diabetes | Active and synergistic with GLP-1 |
| May cause weight gain | Tirzepatide causes significant weight loss |
| Unclear role | GIP + GLP-1 = greater than GLP-1 alone |
Key insight: GIP may enhance the metabolic benefits of GLP-1, particularly for weight loss.
Clinical Trial Results
SURPASS Trials Program
The SURPASS program compared tirzepatide to other diabetes medications:
| Trial | Comparison | Tirzepatide Results |
|---|---|---|
| SURPASS-1 | Placebo (early diabetes) | A1C reduction 1.8-2.6% |
| SURPASS-2 | Semaglutide 1 mg | A1C reduction 2.0% vs 1.9% (semaglutide) |
| SURPASS-3 | Basal-bolus insulin | A1C reduction 2.1% vs 1.2% (insulin) |
| SURPASS-4 | Basal insulin + prandial | A1C reduction 2.3% vs 1.9% (insulin) |
| SURPASS-5 | Placebo (after insulin) | A1C reduction 2.0% |
Weight Loss Results
| Trial | Tirzepatide Weight Loss | Comparison |
|---|---|---|
| SURPASS-2 | -7.6 kg (5 mg) to -12.9 kg (15 mg) | Semaglutide: -6.2 kg |
| SURPASS-3 | -7.5 kg (5 mg) to -12.0 kg (15 mg) | Insulin: +2.2 kg (gain) |
At the 15 mg dose:
- Average weight loss: 15-22%
- 89% of patients lost ≥ 5% body weight
- 57% lost ≥ 15% body weight
- 30% lost ≥ 20% body weight
FDA Indications and Dosing
FDA Approval
| Indication | Details |
|---|---|
| Type 2 diabetes | Approved May 2022 |
| Weight management | Under review (expected 2023/2024) |
Available Doses
| Dose | Use | A1C Reduction | Weight Loss |
|---|---|---|---|
| 2.5 mg | Starting dose | ~1.2% | ~3-5% |
| 5 mg | Therapeutic dose | ~1.7% | ~7-10% |
| 7.5 mg | Therapeutic dose | ~1.9% | ~10-12% |
| 10 mg | Therapeutic dose | ~2.0% | ~12-15% |
| 12.5 mg | Therapeutic dose | ~2.2% | ~15-18% |
| 15 mg | Maximum dose | ~2.6% | ~15-22% |
Titration Schedule
| Week | Dose |
|---|---|
| Weeks 1-4 | 2.5 mg weekly |
| Weeks 5-8 | 5 mg weekly |
| Every 4 weeks | Increase by 2.5 mg if needed |
Start at 2.5 mg to minimize GI side effects. The 2.5 mg dose is primarily for titration—it has minimal glucose-lowering effect.
Side Effects
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 10-25% | Dose-dependent; improves over time |
| Vomiting | 5-10% | Usually during titration |
| Diarrhea | 5-10% | Usually mild |
| Abdominal pain | 5-8% | Upper abdominal |
| Decreased appetite | 5-10% | Actually helps weight loss |
| Constipation | 3-5% | Manage with fiber/fluids |
| Injection site reactions | 2-5% | Redness, itching |
Managing GI Side Effects
| Strategy | How |
|---|---|
| Start low, go slow | Use 4-week titration intervals |
| Eat smaller meals | Especially during titration |
| Avoid high-fat foods | Can worsen nausea |
| Stay hydrated | Important if vomiting/diarrhea |
| Time your dose | Take on same day each week |
| Be patient | Side effects typically improve 4-8 weeks after each dose increase |
Serious but Rare Side Effects
| Concern | Risk | Monitoring |
|---|---|---|
| Pancreatitis | Very rare | Prompt evaluation of severe abdominal pain |
| Gallbladder disease | Slightly increased | Be aware of symptoms |
| Medullary thyroid cancer | Theoretical (animal data) | Avoid if personal/family history |
| Hypoglycemia | Risk increased with insulin/sulfonylureas | May need to reduce other medications |
Tirzepatide vs. Other Medications
Compared to Semaglutide (Ozempic)
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| A1C reduction | 2.0-2.6% | 1.0-1.8% |
| Weight loss | 15-22% | 5-15% |
| Convenience | Weekly injection | Weekly injection |
| Side effects | Similar profile | Similar profile |
| Cost | Similar (~$1000/month) | Similar (~$1000/month) |
| Cardiovascular outcome | Ongoing trial | Proven benefit |
Compared to Insulin
| Feature | Tirzepatide | Basal-Bolus Insulin |
|---|---|---|
| A1C reduction | Greater | Slightly less |
| Weight loss | 15-22% loss | 2-5 kg gain |
| Hypoglycemia risk | Low | Significant |
| Convenience | 1 weekly injection | 2-4+ injections daily |
| Cost | High | Variable (often lower) |
Compared to Other Weight Loss Medications
| Medication | Weight Loss | Diabetes Benefit |
|---|---|---|
| Tirzepatide | 15-22% | Yes, primary indication |
| Semaglutide 2.4 mg (Wegovy) | 12-15% | Yes (Ozempic 1 mg) |
| Liraglutide 3 mg (Saxenda) | 5-10% | Yes (Victoza 1.8 mg) |
| Phentermine/topiramate | 5-10% | No |
| Bupropion/naltrexone | 3-5% | No |
Who Should Consider Tirzepatide?
Ideal Candidates
The 2025 ADA guidelines recommend tirzepatide as a first-line option (with metformin) for patients with:
| Characteristic | Why Tirzepatide |
|---|---|
| BMI ≥ 30 OR BMI ≥ 27 with comorbidity | Significant weight loss benefit |
| High A1C (≥ 9%) | Potent glucose-lowering |
| Need for both glucose and weight management | Dual benefit |
| Cardiovascular risk | Positive CV outcome trial results |
| Established CVD | Alternative to GLP-1 with CV benefit |
Consider Tirzepatide If You
- Have tried other medications without reaching A1C goal
- Need significant weight loss for health reasons
- Have high cardiovascular risk
- Want to minimize diabetes medications (one injection vs multiple pills)
- Can afford the cost (or have insurance coverage)
Cost and Access
Pricing
| Item | Approximate Cost |
|---|---|
| Mounjaro (tirzepatide) | $900-$1,200/month |
| Manufacturer savings card | May reduce to as low as $25 for eligible patients |
Insurance Coverage
- Most Medicare Part D plans cover Mounjaro for type 2 diabetes
- Commercial insurance coverage varies
- Prior authorization often required
- Step therapy may apply (try metformin first)
Patient Assistance
Eli Lilly offers:
- Mounjaro Savings Card for commercially insured patients
- Lilly Cares for uninsured/underinsured patients who qualify
Practical Considerations
Administration
- Weekly subcutaneous injection (abdomen, thigh, or upper arm)
- Same day each week (pick a memorable day)
- Can be taken with or without food
- Does not require timing with meals (unlike some diabetes medications)
Storage
| Condition | Storage |
|---|---|
| Unopened pens | Refrigerate (36-46°F) until expiration |
| Opened pens | Room temperature or refrigerated for up to 30 days |
| Extreme temperatures | Avoid (don't leave in hot car or freeze) |
Missed Dose
- If within 4 days of scheduled dose: Take as soon as remembered
- If more than 4 days: Skip and take next scheduled dose
- Return to regular schedule at next injection day
Future of Tirzepatide
Potential Future Indications
| Indication | Status |
|---|---|
| Weight management (obesity) | Under FDA review (SURMOUNT trials) |
| Obstructive sleep apnea | Being studied |
| Heart failure | Early trials underway |
| NASH (fatty liver disease) | Being studied |
SURMOUNT Trials (Weight Management)
| Trial | Status | Results So Far |
|---|---|---|
| SURMOUNT-1 | Completed | 16% weight loss at 72 weeks |
| SURMOUNT-2 | Completed | 15% weight loss vs 2% placebo |
| SURMOUNT-3 | Completed | 16% weight loss (intensive lifestyle intervention) |
| SURMOUNT-4 | Ongoing | Maintenance after weight loss |
| SURMOUNT-5 | Ongoing | Long-term efficacy/safety |
Key Takeaways
- Tirzepatide is a dual GIP/GLP-1 agonist—first in its class
- Lowers A1C by up to 2.6%—more than any other diabetes medication
- Causes 15-22% weight loss—more than most bariatric surgery results
- Administered as weekly injection at doses from 2.5 to 15 mg
- Side effects mostly GI and improve over time
- First-line option for patients with high BMI and type 2 diabetes
- Expensive but manufacturer assistance programs available
FAQ Section
What is tirzepatide used for?
Tirzepatide (Mounjaro) is FDA-approved for treating type 2 diabetes. It lowers blood sugar by activating both GIP and GLP-1 receptors. It's also being studied for weight management, with potential FDA approval for obesity.
Is Mounjaro better than Ozempic?
In clinical trials, tirzepatide (Mounjaro) was more effective than semaglutide 1 mg (Ozempic) for both A1C reduction (2.0% vs 1.9%) and weight loss (12% vs 6%). However, direct comparison with Ozempic 2 mg is limited.
How does tirzepatide cause weight loss?
Tirzepatide causes weight loss through multiple mechanisms: reducing appetite (acting on brain hunger centers), increasing fullness (slowing stomach emptying), and possibly increasing energy expenditure (GIP effect on fat metabolism).
What are the side effects of tirzepatide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and abdominal pain. These usually occur during dose titration and improve over time. Other side effects include decreased appetite, constipation, and injection site reactions.
Can tirzepatide be used with insulin?
Yes, tirzepatide can be used with insulin, but caution is needed as the combination increases hypoglycemia risk. The insulin dose may need to be reduced when starting tirzepatide. Close blood sugar monitoring is essential.
Sources:
- American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1)
- SURPASS-1, -2, -3, -4, -5 trials
- SURMOUNT-1, -2, -3 trials
- Lilly Mounjaro Information
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about your health, treatment, or care. Individual circumstances vary, and what is appropriate for one person may not be appropriate for another.
If you are experiencing a medical emergency, call 911 (or your local emergency number) immediately.